<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR866.html">Part 866
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 866.3510  Rubella virus serological reagents.
                            </h3>
                            <p class="depth1"><em>(a)</em> Identification. Rubella virus serological reagents are devices  that consist of antigens and antisera used in serological tests to  identify antibodies to rubella virus in serum. The identification aids  in the diagnosis of rubella (German measles) or confirmation of a  person's immune status from past infections or immunizations and  provides   epidemiological information on German measles. Newborns infected in the  uterus with rubella virus may be born with multiple congenital defects  (rubella syndrome).</p><p class="depth1"><em>(b)</em> Classification. Class II. The special controls for this device  are:</p><p class="depth2"><em>(1)</em> National Committee for Clinical Laboratory Standards':</p><p class="depth3"><em>(i)</em> 1/LA6 ``Detection and Quantitation of Rubella IgG Antibody:  Evaluation and Performance Criteria for Multiple Component Test  Products, Speciment Handling, and Use of the Test Products in the  Clinical Laboratory, October 1997,''</p><p class="depth3"><em>(ii)</em> 1/LA18 ``Specifications for Immunological Testing for  Infectious Diseases, December 1994,''</p><p class="depth3"><em>(iii)</em> D13 ``Agglutination Characteristics, Methodology, Limitations,  and Clinical Validation, October 1993,''</p><p class="depth3"><em>(iv)</em> EP5 ``Evaluation of Precision Performance of Clinical Chemistry  Devices, February 1999,'' and</p><p class="depth3"><em>(v)</em> EP10 ``Preliminary Evaluation of the Linearity of Quantitive  Clinical Laboratory Methods, May 1998,''</p><p class="depth2"><em>(2)</em> Centers for Disease Control's:</p><p class="depth3"><em>(i)</em> Low Titer Rubella Standard,</p><p class="depth3"><em>(ii)</em> Reference Panel of Well Characterized Rubella Sera, and</p><p class="depth2"><em>(3)</em> World Health Organization's International Rubella Standard.  [47 FR 50823, Nov. 9, 1982, as amended at 52 FR 17734, May 11, 1987; 65  FR 17144, Mar. 31, 2000]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
